Tradestie Institutional Equity Comparison Engine

IMDX vs CDNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDNA Overall Edge

CDNA Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IMDX trades at N/M Forward P/E with -1883.2% operating margin (+115.0% YoY revenue) versus CDNA at 46.0x Forward P/E and 1.6% operating margin (+39.3% YoY). In options structure, IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro) against CDNA sits in CONSOLIDATION (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CDNA
IMDX N/M vs CDNA 46.0x Fwd P/E
Growth & Margin Winner CDNA
Op Margin -1883.2% vs 1.6% ยท YoY +115.0% vs +39.3%
Momentum & Technical Winner CDNA
1Y -73.8% vs +356.4% ยท 52W Pos 3% vs 75%
Options & Structure Winner CDNA
BREAKDOWN (12th %ile IV) vs CONSOLIDATION (20th %ile IV)
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
1M Return -45.03%
1Y Return -73.78%
Forward P/E N/M
Unified AI Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
CDNA NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$71.92
-3.39% 1D
Market Cap $3.9B
1M Return +1.67%
1Y Return +356.35%
Forward P/E 46.0x
Unified AI Score
32.0 / 100 SELL
Tech 31.0 Fund 48.0 Flow 70.0 Mom 36.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMDX -73.78% CDNA +356.35% Spread: +430.13 pp (CDNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IMDX Revenue CDNA Revenue IMDX Op. Margin CDNA Op. Margin Margin Edge
FY2018 N/A $80M N/A -20.3% CDNA
FY2019 N/A $130M N/A -19.3% CDNA
FY2020 $0M $190M -2443.3% -11.7% CDNA
FY2021 $0M $300M -2444.3% -10.0% CDNA
FY2022 $0M $320M -1878.6% -24.0% CDNA
FY2023 $0M $280M -1672.4% -72.5% CDNA
FY2024 $0M $330M -3245.1% 12.2% CDNA
FY2025 $0M $380M -1260.8% -8.1% CDNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMDX (3) vs CDNA (7)
Institutional Metric IMDX CDNA Criterion Row Winner
Market Capitalization Scale $52.1M $3.9B Larger Scale CDNA
Trailing P/E Ratio Valuation N/M 31.5x Lower Multiple CDNA
Forward P/E Ratio Valuation N/M 46.0x Lower Multiple CDNA
Revenue Growth (YoY) Growth +115.0% +39.3% Higher Growth IMDX
Operating Margin (TTM) Profitability -1883.2% 1.6% Higher Margin CDNA
Net Profit Margin Profitability 0.0% 25.9% Higher Margin CDNA
Return on Equity (ROE) Capital Efficiency -23603.1% 33.0% Higher ROE CDNA
52-Week Range Position Momentum 3% ($2โ€“$8) 75% ($15โ€“$91) Stronger Trend CDNA
Beta / 30D Volatility Risk Regime 2.91ฮฒ ยท 76% Vol 1.22ฮฒ ยท 97% Vol Lower Realized Risk IMDX
Unified Institutional Score Composite Signal 45.5 / 100 (HOLD) 32.0 / 100 (SELL) Higher Composite IMDX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMDX vs CDNA Buy Guide
IMDX BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live IMDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live CDNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMDX nor CDNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.